Introduction:
The article discusses the RevIT™ AAV Enhancer, a tool that can significantly increase the production of adeno-associated virus (AAV) genomes in gene therapy manufacturing. The goal of gene therapies is to target genetic diseases, and to do this effectively, all components of the manufacturing process need to be optimized. The RevIT™ AAV Enhancer can increase AAV genome titers and be integrated into existing AAV manufacturing workflows, leading to cost savings in gene therapy manufacturing.
- The RevIT™ AAV Enhancer can increase AAV genome titers across multiple serotypes and transfection platforms, including the TransIT-VirusGEN® Transfection Reagent and polymeric transfection reagents.
- Simple optimization allows for the easy integration of the RevIT™ AAV Enhancer into existing AAV manufacturing workflows.
- The use of the RevIT™ AAV Enhancer can lead to considerable savings in AAV-based gene therapy manufacturing costs, as it allows for a decrease in the amount of plasmid DNA required.
Conclusion:
The RevIT™ AAV Enhancer is a valuable tool in gene therapy manufacturing. Its ability to increase AAV genome titers, integrate into existing workflows, and reduce manufacturing costs makes it a promising solution for the production of AAV-based gene therapies.
